200 related articles for article (PubMed ID: 15780373)
21. Phase II trial evaluating a docetaxel-capecitabine combination as treatment for hormone-refractory prostate cancer.
Ferrero JM; Chamorey E; Oudard S; Dides S; Lesbats G; Cavaglione G; Nouyrigat P; Foa C; Kaphan R
Cancer; 2006 Aug; 107(4):738-45. PubMed ID: 16826591
[TBL] [Abstract][Full Text] [Related]
22. Randomized Phase II study comparing paclitaxel and carboplatin versus mitoxantrone in patients with hormone-refractory prostate cancer.
Cabrespine A; Guy L; Khenifar E; Curé H; Fleury J; Penault-Llorca F; Kwiatkowski F; Barthomeuf C; Chollet P; Bay JO
Urology; 2006 Feb; 67(2):354-9. PubMed ID: 16442593
[TBL] [Abstract][Full Text] [Related]
23. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone.
Rosenberg JE; Weinberg VK; Kelly WK; Michaelson D; Hussain MH; Wilding G; Gross M; Hutcheon D; Small EJ
Cancer; 2007 Aug; 110(3):556-63. PubMed ID: 17577218
[TBL] [Abstract][Full Text] [Related]
24. Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma.
Sinibaldi VJ; Carducci MA; Moore-Cooper S; Laufer M; Zahurak M; Eisenberger MA
Cancer; 2002 Mar; 94(5):1457-65. PubMed ID: 11920502
[TBL] [Abstract][Full Text] [Related]
25. A phase II study of weekly paclitaxel/estramustine/carboplatin in hormone-refractory prostate cancer.
Berry W; Friedland D; Fleagle J; Jackson D; Ilegbodu D; Boehm KA; Asmar L
Clin Genitourin Cancer; 2006 Sep; 5(2):131-7. PubMed ID: 17026801
[TBL] [Abstract][Full Text] [Related]
26. Activity of weekly paclitaxel in advanced hormone-refractory prostate cancer.
Chiappino I; Destefanis P; Addeo A; Galetto A; Cucchiarale G; Munoz F; Zitella A; Ferrando U; Fontana D; Ricardi U; Tizzani A; Bertetto O
Am J Clin Oncol; 2007 Jun; 30(3):234-8. PubMed ID: 17551298
[TBL] [Abstract][Full Text] [Related]
27. Docetaxel, estramustine and prednisone for hormone-refractory prostate cancer: a single-center experience.
Boehmer A; Anastasiadis AG; Feyerabend S; Nagele U; Kuczyk M; Schilling D; Corvin S; Merseburger AS; Stenzl A
Anticancer Res; 2005; 25(6C):4481-6. PubMed ID: 16334130
[TBL] [Abstract][Full Text] [Related]
28. Docetaxel (Taxotere)-based chemotherapy for hormone-refractory and locally advanced prostate cancer.
Oh WK; Kantoff PW
Semin Oncol; 1999 Oct; 26(5 Suppl 17):49-54. PubMed ID: 10604270
[TBL] [Abstract][Full Text] [Related]
29. Docetaxel chemotherapy for metastatic hormone refractory prostate cancer as first-line palliative chemotherapy and subsequent re-treatment: Birmingham experience.
Ansari J; Hussain SA; Zarkar A; Tanguay JS; Bliss J; Glaholm J
Oncol Rep; 2008 Oct; 20(4):891-6. PubMed ID: 18813832
[TBL] [Abstract][Full Text] [Related]
30. Weekly docetaxel and bortezomib as first-line treatment for patients with hormone-refractory prostate cancer: a Minnie Pearl Cancer Research Network phase II trial.
Hainsworth JD; Meluch AA; Spigel DR; Barton J; Simons L; Meng C; Gould B; Greco FA
Clin Genitourin Cancer; 2007 Mar; 5(4):278-83. PubMed ID: 17553208
[TBL] [Abstract][Full Text] [Related]
31. Dose escalation study of intravenous estramustine phosphate in combination with Paclitaxel and Carboplatin in patients with advanced prostate cancer.
Kelly WK; Zhu AX; Scher H; Curley T; Fallon M; Slovin S; Schwartz L; Larson S; Tong W; Hartley-Asp B; Pellizzoni C; Rocchetti M
Clin Cancer Res; 2003 Jun; 9(6):2098-107. PubMed ID: 12796374
[TBL] [Abstract][Full Text] [Related]
32. Preliminary evaluation of a short course of estramustine phosphate and docetaxel (Taxotere) in the treatment of hormone-refractory prostate cancer.
Sinibaldi VJ; Carducci M; Laufer M; Eisenberger M
Semin Oncol; 1999 Oct; 26(5 Suppl 17):45-8. PubMed ID: 10604269
[TBL] [Abstract][Full Text] [Related]
33. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer.
Hudes GR; Nathan F; Khater C; Haas N; Cornfield M; Giantonio B; Greenberg R; Gomella L; Litwin S; Ross E; Roethke S; McAleer C
J Clin Oncol; 1997 Sep; 15(9):3156-63. PubMed ID: 9294479
[TBL] [Abstract][Full Text] [Related]
34. Weekly docetaxel as second line treatment after mitozantrone for androgen-independent prostate cancer.
Joshua AM; Nordman I; Venkataswaran R; Clarke S; Stockler MR; Boyer MJ
Intern Med J; 2005 Aug; 35(8):468-72. PubMed ID: 16176469
[TBL] [Abstract][Full Text] [Related]
35. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
Efstathiou E; Bozas G; Kostakopoulos A; Kastritis E; Deliveliotis C; Antoniou N; Skarlos D; Papadimitriou C; Dimopoulos MA; Bamias A
Urology; 2005 Jan; 65(1):126-30. PubMed ID: 15667877
[TBL] [Abstract][Full Text] [Related]
36. Prospective study of estramustine phosphate for hormone refractory prostate cancer patients following androgen deprivation therapy.
Hirano D; Minei S; Kishimoto Y; Yamaguchi K; Hachiya T; Yoshida T; Yoshikawa T; Endoh M; Yamanaka Y; Yamamoto T; Satoh Y; Ishida H; Okada K; Takimoto Y
Urol Int; 2005; 75(1):43-9. PubMed ID: 16037707
[TBL] [Abstract][Full Text] [Related]
37. A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of cancer and leukemia group B Trial 9780.
Savarese D; Taplin ME; Halabi S; Hars V; Kreis W; Vogelzang N
Semin Oncol; 1999 Oct; 26(5 Suppl 17):39-44. PubMed ID: 10604268
[TBL] [Abstract][Full Text] [Related]
38. A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapy.
Beer TM; Ryan C; Alumkal J; Ryan CW; Sun J; Eilers KM
Anticancer Drugs; 2010 Apr; 21(4):433-8. PubMed ID: 20016365
[TBL] [Abstract][Full Text] [Related]
39. A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813.
Oh WK; Halabi S; Kelly WK; Werner C; Godley PA; Vogelzang NJ; Small EJ;
Cancer; 2003 Dec; 98(12):2592-8. PubMed ID: 14669278
[TBL] [Abstract][Full Text] [Related]
40. Weekly paclitaxel plus estramustine combination therapy in hormone-refractory prostate cancer: a pilot study.
Kuruma H; Fujita T; Shitara T; Egawa S; Yokoyama E; Baba S
Int J Urol; 2003 Sep; 10(9):470-5. PubMed ID: 12941125
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
